UroGen Pharma price target raised to $16 from $3 at Goldman Sachs
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Is HPE the Next Big AI Stock? Goldman Sachs Weighs In
Hewlett-Packard Enterprise Company (NYSE:HPE) is one of the On July 23, Goldman Sachs analyst Michael Ng reinstated coverage on the stock with a 'Neutral' rating and a price target of $22. The rating follows HPE's acquisition of Juniper Networks. According to the firm, HPE's expanded portfolio has allowed it to sustain its position as second-best in enterprise/campus networking while becoming a stronger competitor in the data center segment. Even though the firm maintains a positive outlook toward the company's networking business, it maintains a Neutral stance on the stock due to ongoing challenges in the Server and Hybrid Cloud divisions. A financial analyst standing in front of a screen with the ratings of the company provided by the NRSRO. The bank anticipates HPE's earnings per share at $1.80 for fiscal 2025, $2.23 for fiscal 2026, and $2.42 for fiscal 2027. Hewlett Packard Enterprise Company (NYSE:HPE), an American multinational technology company, provides high-performance computing systems, AI software, and data storage solutions for running complex AI workloads. While we acknowledge the potential of HPE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
9 hours ago
- Yahoo
Regeneron Pharmaceuticals, Inc. (REGN) Acquires 23andMe Assets in $256M Deal
We recently compiled a list of Regeneron Pharmaceuticals, Inc. tops our list for being one of the most undervalued healthcare stocks. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most undervalued stocks. It is a leading American biotech company specializing in treatments for serious diseases across ophthalmology, immunology, oncology, and rare conditions. The company is known for integrating genetics and technology into its drug discovery efforts and continues to grow through internal innovation and strategic acquisitions. In a major move, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is acquiring most of 23andMe's assets for $256 million, including its personal genome service, research services, biobank, and associated data. This will expand the business's access to genetic information from 15 million individuals (with 80% consenting to research use), enhancing its existing warehouse of 3 million anonymized samples. The acquisition significantly boosts Regeneron's capabilities in genetics-guided drug development and precision medicine. The vast dataset will help identify new drug targets, refine clinical trial designs, and improve patient stratification. This positions the corporation to lead the integration of real-world genomic data into personalized healthcare. A pharmacist at work in their online pharmacy checking over orders for pharmaceutical products. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) continues to advance its pipeline with FDA priority reviews for Dupixent (bullous pemphigoid) and Linvoseltamab (multiple myeloma), as well as promising late-stage results for EYLEA HD in eye disorders. The firm's focus remains on leveraging data and science to drive innovative, effective therapies. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
16 hours ago
- Business Insider
Chubb (CB) Receives a Hold from Goldman Sachs
In a report released on July 24, Robert Cox CFA from Goldman Sachs maintained a Hold rating on Chubb, with a price target of $299.00. The company's shares closed yesterday at $269.15. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cox CFA covers the Financial sector, focusing on stocks such as Aon, Brown & Brown, and Progressive. According to TipRanks, Cox CFA has an average return of 10.8% and a 76.56% success rate on recommended stocks. In addition to Goldman Sachs, Chubb also received a Hold from Piper Sandler's Paul Newsome in a report issued on July 24. However, yesterday, TR | OpenAI – 4o reiterated a Buy rating on Chubb (NYSE: CB). CB market cap is currently $108.3B and has a P/E ratio of 11.92. Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CB in relation to earlier this year. Last month, Michael Atieh, a Director at CB sold 538.00 shares for a total of $154,707.28.
